Benzimidazole, pyridine and specialty intermediates for API synthesis.
Enteric Coated Pellets • Sustained Release Pellets • MUPS Pellets • DC Granules • APIs • Intermediates
Pharmaceutical intermediates are the compounds produced at each stage of an API synthesis route. A reliable intermediate supply de-risks API manufacturing, because a single missing stage can stop the whole route.
Rraynex's intermediates focus on the proton pump inhibitor family: mercaptobenzimidazoles, chloromethyl pyridine hydrochlorides and the sulfide intermediates used in omeprazole, pantoprazole, rabeprazole and lansoprazole synthesis. The range also includes anthelmintic, gastrointestinal, CNS, cardiometabolic and veterinary intermediates.
Each intermediate below has its own page showing the therapeutic route it belongs to and how to request specifications.
Sulfur-bearing benzimidazole intermediate supporting Lansoprazole, Rabeprazole, and Dexlansoprazole synthesis. Delivered with tight impurity and residual solvent controls for reliable PPI manufacturing (CAS 583-39-1). End use: Lansoprazole, Rabeprazole, Dexlansoprazole.
Key benzimidazole intermediate for methoxy-substituted proton pump inhibitors. Managed particle control and sulphur profile aid consistent downstream coupling (CAS 37052-78-1). End use: Lansoprazole, Rabeprazole, Dexlansoprazole.
Activated pyridine salt used in assembling the Omeprazole side chain. Controlled chloromethyl content and low colour ensure clean coupling reactions (CAS 86604-75-3). End use: Omeprazole.
Coupled benzimidazole intermediate feeding final Omeprazole formation. Produced under nitrogen with sulphide controls to minimise oxidative by-products (CAS 73590-85-9). End use: Omeprazole.
Difluoromethoxy benzimidazole scaffold enabling Pantoprazole sulphide formation. Managed fluoride content supports regulatory-compliant impurity profiles (CAS 97963-62-7). End use: Pantoprazole.
Chloro pyridine intermediate (Pantoprazole chloro) optimised for high assay and controlled chloride levels, expediting nucleophilic substitution with benzimidazole partners (CAS 72830-09-2). End use: Pantoprazole.
Pantoprazole sulphide intermediate manufactured under controlled oxidation states to facilitate clean sulfoxidation steps (CAS 102625-64-9). End use: Pantoprazole.
Ethoxy-substituted benzimidazole intermediate supporting Afobazol and Obenoxazine syntheses. Produced with low residual solvents to simplify downstream crystallisation (CAS 55489-15-1). End use: Afobazol, Obenoxazine.
Activated pyridine salt that anchors Rabeprazole side-chain construction. Chloride and moisture controls deliver consistent coupling performance (CAS 153259-31-5). End use: Rabeprazole.
Beyond catalogue products, Rraynex offers pellet development from pilot to commercial scale, pellet coating, contract manufacturing and technology transfer. The team can share DMF access, stability data and custom formulation options for your project.